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ABSTRACT: Data sharing is essential for a better under-
standing of genetic disorders. Good phenotype coding plays a
key role in this process. Unfortunately, the two most widely
used coding systems in medicine, ICD-10 and SNOMED-
CT, lack information necessary for the detailed classification
and annotation of rare and genetic disorders. This prevents
the optimal registration of such patients in databases and
thus data-sharing efforts. To improve care and to facilitate
research for patients with metabolic disorders, we developed
a new coding system for metabolic diseases with a dedi-
cated group of clinical specialists. Next, we compared the
resulting codes with those in ICD and SNOMED-CT. No
matches were found in 76% of cases in ICD-10 and in 54%
in SNOMED-CT. We conclude that there are sizable gaps
in the SNOMED-CT and ICD coding systems for metabolic
disorders. There may be similar gaps for other classes of rare
and genetic disorders. We have demonstrated that expert
groups can help in addressing such coding issues. Our coding
system has been made available to the ICD and SNOMED-
CT organizations as well as to the Orphanet and HPO orga-
nizations for further public application and updates will be
published online (www.ddrmd.nl and www.cineas.org).
Hum Mutat 34:967–973, 2013. C© 2013 Wiley Periodicals, Inc.
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Introduction
Data sharing is essential for a better understanding of rare genetic
disorders and the underlying genetic defects. Good phenotype cod-
ing plays a key role in this process and also in general in processes
where phenotype data need to be entered into clinical registries,
genotype–phenotype databases, and biobanks, and shared between
them. Such initiatives to register, combine, and exchange clinical
and research data are pivotal in supporting research and improving
healthcare [Jones et al., 2011; Richesson and Vehik, 2010].
Rare diseases are life threatening or chronically debilitating dis-
eases with a prevalence of up to five per 10,000 inhabitants in the
European Union (EU). It is estimated that there are at least 5,000
rare diseases, many of them genetic, affecting 6%–8% of the total
population in the EU, which implies a minimum 27 million people
in the EU are affected [European Medicines Agency (EMA), 2007].
In the United States, the Rare Disease Act of 2002 also defined rare
disease according to prevalence, specifically “any disease or condi-
tion that affects less than 200,000 persons in the United States,” or
about one in 1,500 people. Although there are no disease-modifying
therapies formost rare diseases, the passing of the 1983U.S. Orphan
Drug Act [Food and Drug Administration] and European legisla-
tion in 2000 [European Parliament. Regulation (EC) No. 141/2000]
stimulated new research lines by creating financial incentives and
other supportive measures for developers of new drugs to treat peo-
ple with rare diseases [Talele et al., 2010]. It is expected that many
more rare diseases will become amenable to treatment within the
next few decades.
The need to improve research and care in the field of rare disor-
ders, which can be strongly supported by the sharing and combin-
ing of data on these rare patients, has also been recognized by the
Council of the European Union. Through their European Action in
the Field of Rare Diseases [Official Journal of the European Union,
Council recommendation of 8 June 2009 on an action in the field
of rare disease], signed in 2009, the EU member states committed
themselves to establishing and implementing a national rare disease
action plan and to cooperating at a European level on this health
issue. The European Action stated that member states should “aim
C© 2013 WILEY PERIODICALS, INC.
to ensure that rare diseases are adequately coded and traceable in all
health information systems, encouraging an adequate recognition
of the disease in the national healthcare and reimbursement systems
based on the ICD.”
Unfortunately, the two most widely used coding systems in
medicine—ICD (the WHO’s International Classification of Dis-
eases, www.who.int/classifications/icd) and SNOMED-CT (Sys-
tematized Nomenclature of Medicine Clinical Terminology,
www.ihtsdo.org)—lack essential details for classifying and anno-
tating rare and hereditary disorders. This is a barrier to the optimal
registration of patients with these disorders in databases, and to
much needed data-sharing efforts, such as those in the Human Var-
iome Project (http://www.humanvariomeproject.org).
Our study addresses this problem formetabolic diseases, a partic-
ular hereditary subgroup of rare disorders. Metabolic diseases, also
referred to as inborn errors of metabolism, are generally monogenic
defects resulting in a deficient activity in an enzyme or a trans-
porter in a pathway of cellular metabolism [Scriver et al., 2001]. The
number of recognized metabolic diseases is continually increasing
because of the advances in knowledge and diagnostic laboratory
techniques. Most metabolic diseases are extremely rare (less than
one per 50,000 inhabitants), although all metabolic diseases com-
binedhave an estimated, relatively high birth prevalence of up to one
per 800 newborns [Sanderson et al., 2006]. In the Netherlands, we
decided to build a registry for patients withmetabolic disorders and
also to optimize the codes for national use in medical and clinical
genetics. With these purposes in mind, we developed, with a ded-
icated group of clinical specialists, a clinically oriented annotation
system for metabolic disorders based on two existing national cod-
ing systems. To assess the potential value of adding our annotation
system to ICD and SNOMED-CT, we compared the three systems
and identified large gaps in both ICD and SNOMED-CT. To the best
of our knowledge, we are the first to actually quantify these gaps for
a specific field of rare diseases.
Materials and Methods
Study Overview
We combined and expanded two existing coding systems for
metabolic diseases, the DDRMD (Dutch Diagnosis and Registra-
tion ofMetabolic Diseases, www.ddrmd.nl) and a subset of CINEAS
(Dutch center for disease code development and distribution to the
clinical genetics community, www.cineas.org) to develop amore de-
tailed and strongly clinically oriented coding system. The DDRMD
was set up by specialists in metabolic disorders, whereas CINEAS
was initiated by clinical geneticists. Both systems were originally
developed independent of each other and born out of the need to
have more extensive coding system available than the ones offered
by SMOMED and ICD. The primary purpose of each of our original
coding systems was improving patient classification and retrieval.
We used the DDRMD as a starting point for extending the coding
system of metabolic diseases because this system had already been
used for more than 10 years bymetabolic specialists in clinical prac-
tice.Wematched and enriched these systems in a three-step process,
exemplified in a flowchart (Figure 1). A list of criteria for including
codes in the coding system was drawn up for the matching pro-
cess (Table 1). To facilitate cross-linking, but also to investigate the
extent to which codes were lacking in ICD and SNOMED-CT, we
checked and updated existing mappings to these two international
systems.
DDRMD (Background, Origin, and Objective)
TheDDRMD is a collaborative project of all the clinicalmetabolic
centers in the Netherlands. It was started in 2001 and over 5,000 pa-
tients havebeen registered so far,with almost 300differentmetabolic
diseases. The main reason for initiating the DDRMD was that de-
spite the various diagnosis registration systems used in hospitals,
it was proving difficult to retrieve patients with metabolic diseases
from these registers. Because there was no disease-specific registra-
tion for metabolic diseases, it was impossible to analyze relevant
patient data, either for research or for care purposes.
In the DDRMD, patient data are registered by one metabolic spe-
cialist per metabolic center (see Figure 2) via a secureWeb server. In
addition, relevant data on newborns referred because of an abnor-
mal neonatal screening result indicative for metabolic disease are
also included. The data are used to facilitate research on metabolic
diseases and to provide information on the outcome of the Dutch
newborn screening procedure for metabolic diseases.
CINEAS (Background, Origin, and Objective)
CINEAS is the Dutch center for disease code development and
distribution to the clinical genetics community. It was initiated by
the eight clinical genetics centers responsible for genetic counseling
and diagnostics in the Netherlands in 1992 [Zwamborn-Hanssen
et al., 1997]. It is used in daily practice by the Dutch clinical geneti-
cists and genetic counselors to assign diseases to patients. Presently,
the 55th edition of CINEAS lists more than 5,500 diseases, most
of them rare, and the metabolic diseases form a distinct subset
(Figure 3). A number of Dutch diagnostic DNA laboratories use the
CINEAS system as well, and recently the Danish genetics centers
have decided to adopt CINEAS. Each new edition of the list con-
tains new disease entries submitted by users, after they have been
discussed and approved by a group of experts. The entire process of
submitting and adding new entries to the database is supported by
a Website (www.cineas.nl or www.cineas.org), a paid professional
curator and a quickly responding national expert panel, which has
reduced throughput time to an average of 2 weeks. Local system
administrators upload new editions to their own patient informa-
tion systems, and the Website facilitates searching of the CINEAS
database and is used to publish the new editions. Codes are never
removed from the system, but can be made obsolete and thus no
longer assigned to patients. Entry, modifications, and obsoletion of
codes including dates are saved in theDiagnosisHistory. Cross-links
are provided to OMIM, Online Mendelian Inheritance in Man, a
catalogue of hereditary disorders and their genes (www.omim.org),
and to SNOMED and ICD. Although the codes in CINEAS, in-
cluding the metabolic codes, are nonhierarchical (see Discussion),
individual codes can easily be found in the systemusing the onboard
search engine.
Existing Coding Systems
The most widely used system in medical practice is the
ICD, published by the World Health Organization (version 9
published in 1977, or version 10 in 1999). It is categorized by
the affected organ system, which makes it difficult to use for dis-
eases in which more than one organ is affected, as is the case
for many rare genetic diseases. The WHO is working on the re-
vision of ICD-10, with the aim of publishing ICD-11 in 2015
(www.who.int/classifications/icd/revision).
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Figure 1. Flowchart of building the coding system and quantifying the gaps in ICD-10 and SNOMED-CT.
SNOMED-CT is a coding system, which has been adopted by
many hospital information systems and standards organizations
worldwide as a key coding system. Since 1974, SNOMED-CT has
evolved from a pathology-specific nomenclature into a healthcare
terminology system. There are many studies that have shown the
value of SNOMED-CT in theory, but studies on its use in clinical
practice are relatively rare [Cornet and de Keizer, 2008].
Assessment of Gaps for Metabolic Disease in ICD and
SNOMED-CT
During the final steps of our matching process (Figure 1), for
each code in our system, we chose the most appropriate ICD-10
code as a cross-link, using the online WHO browser (http://apps.
who.int/classifications/icd10/browse/2010/en) and searching with
disease names and synonyms. When no specific disease code was
available, we chose a group name or nonspecific code based on the
etiology, for example, “E79.8 Other disorders of purine and pyrim-
idine metabolism” or “E88.8 other specified metabolic disorder”
(Table 2).
In addition, we mapped as many entries as possible to
the SNOMED-CT International Edition of January 2011, using
CliniClue Explore (http://www.cliniclue.com/) and by searching
SNOMED-CT using disease names and synonyms. We recorded
all the unambiguous mappings and all the possible mappings if
more than one SNOMED-CT code was available. Finally, we calcu-
lated the gaps for metabolic diseases in ICD-10 and SNOMED-CT
as percentages of codes with matches in our coding system.
Table 1. List of Criteria for Including Codes in our Coding System
Number Criteria
1 The disease has to be a separate clinical entity.
2 Is must be likely that the disease is a separate clinical entity; just one
case report in the literature is not enough, unless an enzyme
deficiency or transport defect was demonstrated.
3 No separate entries for gene defects; a gene can, however, be connected
to a disease (no specific mutation is mentioned).
4 No specific entries for groups of diseases.
5 One enzyme defect leads to only one separate code.
Results
Wehavedevelopeda specific coding systemformetabolicdiseases,
currently containing almost 300 different disorders. Every item in
our system has a unique identifier and includes a disease name,
existing synonyms, and mappings to the OMIM catalogue, ICD-10
and SNOMED-CT (example in Table 2). For the unique identifiers,
we used the existing CINEAS codes. The mappings to the other
coding systems can be used for data exchange with other databases
and provide extra search possibilities.
Note that we deviated fromour inclusion criteria (Table 1) for the
groupofmitochondrial diseases.Apart fromthe separate respiratory
chain disorders, we added two general codes for diseases caused by
mitochondrial DNA variations. This is because this particular area
is evolving rapidly and clear classification is not yet possible in all
cases. We expect to be able to create more specific entries for these
diseases in the coming years.
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Figure 2. Data model for DDRMD.
For 214 (76%) of the diseases in our coding system, there was no
specificmatching ICD-10 code andonly an ICD-10 groupname that
was too general for our clinical classification purposes was available
(e.g., ICD-10 code E88.8 “other specified metabolic disorders”).
For 155 (54%) of our codes, it was not possible to map unam-
biguously to SNOMED-CT because for 81 codes (29%), there was
no SNOMED-CT code available and for 72 codes (25%) SNOMED-
CT contained double codes. These duplicates were counted mostly
because the disease and enzyme deficiencywere given separate codes
in SNOMED-CT, but also because toomuch detail in SNOMED-CT
made it difficult to distinguish between group codes and subcodes.
An example is the disease “alpha-N-acetylgalactosaminidase defi-
ciency” for which SNOMED provided mistakingly two codes, one
with three subcodes (Table 2). This shows that despite the size of
the SNOMED system, the unambiguous detail needed in clinical
practice for metabolic diseases is often not available.
We aim to publish incidences and prevalence of individual
metabolic diseases in our coding system online in the spring of
2013. Our coding system is being continuously updated and is
published on www.ddrmd.nl and www.cineas.org in pdf and xml
formats. CINEAS and DDRMD keep existing as two different or-
ganizations, each with a different purpose, now sharing the code
system for metabolic disorders. Requests for additions to and alter-
ations of DDRMD and/or CINEAS users are submitted by email to
info@cineas.nl orddrmd@umcutrecht.nl orbyusinganonlineWeb-
form on the CINEAS Website for registered organizations. These
requests are subsequently discussed in the national CINEAS online
expert panel for approval. The national coordinator of DDRMD is
now a member of the CINEAS expert panel. The coding system has
already been updated using these procedures and now contains 285
diseases.
Continued funding for the classification efforts is provided by
CINEAS (Dutch national disease code development and distribu-
tion center for the clinical genetics community). Our novel coding
system has recently been donated to ICD, SNOMED-CT, and also to
the Human Phenotype Ontology (HPO) (www.human-phenotype-
ontology.org), a promising emerging ontology for phenotypic ab-
normalities, and toOrphanet (www.orpha.net), an important refer-
ence portal for information on rare diseases and orphan drugs, for
further public application. Continuous updates of our system will
be published online.
Discussion
The most widely used classification and coding systems in medi-
cal databases are ICD and SNOMED-CT. Historically, the focus in
the development of these systems has been directed toward classify-
ing common disorders. The development and updating process for
international broad medical coding systems is a highly demanding
task and we acknowledge the important contribution of ICD and
SNOMED-CT to the annotation of common disorders. However,
annotation for rare disorders has been left behind. Collectively, this
group is large and growing steadily because of the identification of
new diseases and improved clinician awareness. Our study demon-
strates large gaps in both ICD (76%) and SNOMED-CT (54%) for
metabolic disorders. On the basis of our clinical experience, we
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Figure 3. Data model for CINEAS—only core tables.
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Table 2. Example from Our Coding System
Disease Synonyms Identifier OMIM ICD-10 SNOMED
Adenylosuccinase deficiency Adenylosuccinate lyase 1573 103050 E79.8 73843004
Aldolase-B deficiency Hereditary fructose intolerance 1318 229600 E74.1 20052008







2286 266100 E88.8 Not available







1539 609241 E88.8 Double codes: 238048001
and 230365004 with
three subcodes
suspect that there may be similar gaps for other types of rare disor-
ders. Such gaps are a barrier to database- and data-sharing efforts.
We have shown that with the help of dedicated clinicians and code
development agencies, the problemof coding gaps for rare disorders
can be successfully addressed.
Developing codes for a rare field of medicine has special chal-
lenges. We observed during the development of our system that
existing hierarchical, “tree,” classification structures, such as those
used in SNOMED-CT and in ICD-10, were proving inconvenient
for our purpose. Such structures, when well developed for the par-
ticular branches, allow for the selection of patients from groups
of disorders rather than those with particular individual disorders.
However, in the rare field of metabolic disorders, these existing tree
structures turned out to be problematic and we dropped our initial
hierarchical approach for several reasons. Firstly, several diseases did
not fit into any specific group or category leading to a risk of mis-
classification. Secondly, several diseases fitted into more than one
group or category leading to significant risk of double entries for
the same disorder. Furthermore, given the explosion of knowledge
in this field of rare genetic diseases, extensive and continuous exper-
tise is needed to update the accuracy of a specialist tree structure.
Given the aim of our coding system to assign diagnostic end codes
to patients and to obtain incidence and prevalence data from our
registry on individual metabolic diseases, a nonhierarchical design
turned out to be functional.With growing knowledge on underlying
molecular pathways, well-fitting metabolic branches of the coding
trees are likely to be developed in the future in the international
community and this will support better data handling on the level
of groups of metabolic disorders.
The World Health Organization has signaled the need to im-
prove ICD-10 for use in the field of rare diseases. A spe-
cial Topic Advisory Group (http://www.who.int/classifications/
icd/TAGs/en/index.html) has been assigned to the subject of rare
diseases to advise the WHO on the current updating and revision
process from ICD-10 to ICD-11 (anticipated publication in 2015).
We recently donated our work to both the ICD and SNOMED-CT
communities to support further code development, and to the Or-
phanet and HPO organizations as well. These organizations are also
contributing to solving annotation problems. The Orphanet orga-
nization (www.orpha.net) has stressed the need to provide well-
designed codes for rare diseases, especially for the purposes of data
sharing and it putsmuch effort into this field [Rath et al., 2012]. The
HPO(http://www.human-phenotype-ontology.org/) is another im-
portant international initiative to support the annotation of genetic
disorders and we are presently collaborating with HPO to further
enrich both coding systems.
We are convinced that the approach we adopted—of code devel-
opment driven by particular clinical and epidemiological needs, and
support for that development from experts working in the clinical
and medical fields of interest—can contribute to the quality of an-
notation for rare diseases, and thus to healthcare for patients with
these diseases.
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